Category: All our news
All our news
ITCC-P4, first company in the world to offer preclinical drug tests for children with cancer
All our news
XenTech will attend AACR Annual Meeting in Orlando (Apr. 14-19 2023)
Philippe, Olivier and Delphine cordially invite you to stop by our Booth#618 to discuss our solid tumor PDX collection to bring your innovative research projects a step further !
All our news
XenTech will attend the World ADC London (Mar.- 13-16th)
Philippe and Olivier cordially invite you to stop by our Booth#12 to discuss our long experience in testing ADCs in our solid tumor PDX collection !
All our news
XenTech will attend the DDR inhibitors Summit 2023 (Boston, Jan. 24-26)
Our Head of R&D Oliver Déas will be delighted to discuss with you as he’ll be attending in person.
All our news
XenTech exhibits at EACR 2022 (Seville, Jun. 20-23 2022)
We’ll be exhibiting at EACR in Seville, stop by booth #50 !
Publications
Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification
Publications
Targeting genome integrity dysfunctions impedes metastatic potency in non-small-cell lung cancer circulating tumor cellderived eXplants
CTC-derived eXplants (CDX) offer systems for mechanistic investigation of CTC metastatic potency and may provide rationale for biology-driven therapeutics.
All our news
XenTech exhibits at AACR Annual Meeting (New Orleans, Apr.8-13 2022)
We’ll be exhibiting at AACR New Orleans from Apr.8th 2022, stop by our booth to chat with us (at last!)
Publications
STING protects breast cancer cells from intrinsic and genotoxic-induced DNA instability via a non-canonical, cell-autonomous pathway – Oncogene, Oct.8 2021
Publications
Paediatric Liver Cancer
A preclinical platform of mouse-transplanted human pediatric liver tumors to evaluate the efficacy of conventional and innovative anticancer therapy